VNRX VolitionRx Limited
VolitionRx Limited (VNRX) is expected to report earnings on November 12, 2026, before the market open. The consensus earnings estimate is a loss of $0.69 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -13.3% since its last earnings release on August 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About VolitionRx Limited
VolitionRX Ltd is a clinical-stage life sciences company. The Company is engaged in developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases.
Sector
Healthcare
Industry
Medical Labs & Research